Macupatide
Highest phase reached
Phase 1
Drug type
Protein
- Listing at source
- Listed
- Highest phase reached
- Phase 1
- Drug type
- Protein
- Drug name
- Macupatide
- ly 3532226
- LY-3532226
- ly3532226
- LY3532226
- macupatide
- Macupatide
- macupatide [INN]
- MACUPATIDE [USAN]
- macupatide inn
- macupatide usan
- CAS registry numbers
- 2923558-68-1
- ChEMBL ID
- CHEMBL6068487
- FDA ingredient codes (UNII)
- YWF427CA5D
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -tide
Investigated indications
- Condition
- Hyperglycemia
- Highest recorded phase
- 1
- Condition identifier
- HP:0003074
- Subject identifier
- D006943
- Condition identifier
- EFO_0001073
- Highest recorded phase
- 1
- Condition identifier
- HP_0001513
- Highest recorded phase
- 2
- Condition identifier
- HP_0001943
- Highest recorded phase
- 1
- Condition identifier
- HP_0003074
- Condition identifier
- HP_0025502
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005147
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0011122
- Highest recorded phase
- 2
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (8)
- A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- A Study of LY3532226 in Healthy Participants
- A Study of LY3532226 in Participants With Obesity
- A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus
- A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus
- A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
- A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes
- A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
In development for (4)
- Hyperglycemia Phase 1
- Obesity disorder Phase 1
- Type 1 diabetes mellitus Phase 1
- Type 2 diabetes mellitus Phase 1